STOCK TITAN

Arcus Biosciences, Inc. - $RCUS STOCK NEWS

Welcome to our dedicated page for Arcus Biosciences news (Ticker: $RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcus Biosciences's position in the market.

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Bank of America Healthcare Conference 2024. The company focuses on developing cancer treatments and will have a live webcast on May 16th, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
-
Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) to present new data from phase 2 studies of novel immuno-oncology combinations at the 2024 ASCO Annual Meeting. The company will showcase updated data from EDGE-Gastric and ARC-9 studies, as well as a trial in progress for VELOCITY-Lung Substudy-03. The presentations highlight potential therapies for upper gastrointestinal, colorectal, and lung cancers, emphasizing the promising outcomes of investigational medicines across multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
conferences clinical trial
-
Rhea-AI Summary
Arcus Biosciences (RCUS) will host a conference call to discuss its first-quarter 2024 financial results and pipeline update. The call will take place on May 8th, 2024, at 1:30 PM PT / 4:30 PM ET. Investors can dial in or access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) granted new employees stock options and restricted stock units as per the 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
-
Rhea-AI Summary
Arcus Biosciences, Inc. granted new employees options to purchase 18,400 shares of common stock and restricted stock units for 9,200 shares. The exercise price per share was $16.47, based on the closing price on March 25, 2024. The equity awards were issued under the 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) granted new employees options to purchase 13,800 shares of common stock and restricted stock units for 6,900 shares. The awards were granted under the 2020 Inducement Plan at an exercise price of $17.99 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
Rhea-AI Summary
Arcus Biosciences (RCUS) will participate in investor conferences in March 2024, including Leerink Global Biopharma Conference and Barclays Global Healthcare Conference. The company aims to showcase its differentiated molecules and combination therapies for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
-
Rhea-AI Summary
Arcus Biosciences, Inc. granted new employees options to purchase 17,600 shares of common stock and restricted stock units for 8,800 shares. The exercise price per share was $19.53, based on the closing price on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
-
Rhea-AI Summary
Arcus Biosciences, Inc. and Gilead announce additional equity investment and modifications to clinical programs, with positive data supporting potential for casdatifan. Arcus reports financial results for Q4 2023, highlighting $1.2 billion in pro forma cash. The company plans six ongoing Phase 3 trials for three distinct programs and has cash runway into 2027. Key partnerships and pipeline updates are detailed in the PR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.87%
Tags
Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) granted new employees options to purchase 71,900 shares at $15.20 per share and restricted stock units for 35,950 shares. The equity awards were granted under the 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Stock Data

1.42B
54.39M
41.17%
59.82%
9.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HAYWARD

About RCUS

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be